GSK plc (BCBA:GSK)
Argentina · Delayed Price · Currency is ARS | Market Cap | 152.29T +54.0% |
| Revenue (ttm) | 59.80T +4.0% |
| Net Income | 10.63T +84.9% |
| EPS | 2,590.57 +86.6% |
| Shares Out | n/a |
| PE Ratio | 14.32 |
| Forward PE | 10.70 |
| Dividend | 586.75 (2.95%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 128 |
| Open | 19,900 |
| Previous Close | 19,800 |
| Day's Range | 19,890 - 20,000 |
| 52-Week Range | 11,150 - 22,760 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent
GSK Gains Orphan Drug Designation for Momelotinib in VEXAS Syndrome Treatment
GSK Gains Orphan Drug Designation for Momelotinib in VEXAS Syndrome Treatment
GSK announces momelotinib granted ODD from U.S. FDA, EMA
GSK (GSK) announced that momelotinib, a JAK inhibitor with a differentiated mechanism of action, has received Orphan Drug Designation, ODD, from the US Food and Drug Administration, FDA, and European…
GSK Receives FDA And EMA Orphan Drug Designations For Momelotinib In VEXAS Syndrome
(RTTNews) - GSK plc (GSK), a commercial-stage biopharmaceutical company, announced that it has received Orphan Drug Designation (ODD) for Ojjaara from the U.S. Food and Drug Administration (FDA) and E...
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Overvalued
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion
The sudden $10.6 billion acquisition of Nuvalent NASDAQ: NUVL by GSK NYSE: GSK violently shatters a lingering mergers and acquisitions (M&A) drought across the mid-cap biotechnology sector.
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal
GSK's record $10.6 billion deal for U.S. company Nuvalent will accelerate the British drugmaker's rebuild of its cancer drug business as it seeks to fend off competition from bigger rivals AstraZenec...
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nuval...
After shedding its cancer business just over a decade ago, GSK's new CEO is building back with a $10.6 billion deal
After shedding its oncology business just over a decade ago, GSK is building it back with a $10.6 billion deal.
Nuvalent (NUVL) Soars Over 39% After GSK Acquisition Amid Mixed Market Trends
Nuvalent (NUVL) Soars Over 39% After GSK Acquisition Amid Mixed Market Trends
Market Today: GSK to Acquire Nuvalent in $10.6B Oncology Deal
Market Today: GSK to Acquire Nuvalent in $10.6B Oncology Deal
GSK steps up cancer fight as new boss Luke Miels signals a change of direction: ALEX BRUMMER
The choice of Aussie Luke Miels as GSK's chief exec, previously a lieutenant of Pascal Soriot at AstraZeneca, signalled a change of direction.
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
GSK Acquires Nuvalent for $10.6 Billion to Enhance Cancer Pipeline
GSK to Acquire Nuvalent for $124 per Share Amid Legal Scrutiny
GSK to Acquire Nuvalent for $124 per Share Amid Legal Scrutiny
Mizuho’s Jared Holz on GSK’s plan to acquire Nuvalent for $10.6 billion
Jared Holz, health care sector strategist at Mizuho Securities, joins 'Squawk on the Street' to discuss GSK’s plan to acquire Nuvalent for $10.6 billion, his view on Eli Lilly, and more.
Stocks to Watch Tuesday: Marvell, Intel, GSK, Vail Resorts
GSK Stock Market Update: Key Developments and Insights
GSK Stock Market Update: Key Developments and Insights
Tuesday's Morning Movers: MU Rebounds, ON PT Increases & GSK Buys NUVL
Diane King Hall discusses this morning's top moving stocks by highlighting Micron (MU) as it rallies back after Friday's sell-off. She also touches on Wells Fargo raising its ON Semiconductor's (ON) p...
Nuvalent downgraded to Hold from Buy at Stifel
Stifel downgraded Nuvalent (NUVL) to Hold from Buy with a price target of $124, down from $135, after GSK (GSK) announced that it has entered into an agreement to acquire…
GSK Agrees to Acquire Nuvalent for $10.6 Billion in Major Oncology Deal, Sending Shares Soaring 39%
GSK acquires Nuvalent for $10.6 billion, enhancing its oncology portfolio with promising lung cancer therapies. The deal offers a 40% premium, reflecting Nuvalent's strong clinical pipeline.
GSK Acquires Nuvalent for $10.6 Billion in Cash
GSK Acquires Nuvalent for $10.6 Billion in Cash
GSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline
GSK to Acquire Nuvalent for $10.6 Billion, Boosting Oncology Pipeline
GlaxoSmithKline Acquires Nuvalent for $10.6 Billion, Stock Soars (NUVL)
GlaxoSmithKline Acquires Nuvalent for $10.6 Billion, Stock Soars (NUVL)
5 Things to Know Before the Stock Market Opens
Stock futures are pointing to a higher open Tuesday as the market looks to extend its recovery from last week's losses; President Trump said last night that the U.S. and Iran are close to a "very, ver...
Nuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
Nuvalent shares catapulted to a record high Tuesday after GSK made an all-cash bid to buy the small biotech company for $10.6 billion.